Alternative Therapeutic Approaches in the Treatment of Primary and Secondary Dedifferentiated and Medullary Thyroid Carcinoma

2011 ◽  
Vol 41 (2) ◽  
pp. 139-148 ◽  
Author(s):  
Kim Biermann ◽  
Hans-Jürgen Biersack ◽  
Amir Sabet ◽  
Viktor Janzen
2008 ◽  
Vol 4 (1) ◽  
pp. 22-32 ◽  
Author(s):  
Martin Schlumberger ◽  
Francesca Carlomagno ◽  
Eric Baudin ◽  
Jean Michel Bidart ◽  
Massimo Santoro

2017 ◽  
Vol 24 (1) ◽  
pp. R1-R12 ◽  
Author(s):  
Giovanni Vitale ◽  
Germano Gaudenzi ◽  
Luisa Circelli ◽  
Marco F Manzoni ◽  
Andrea Bassi ◽  
...  

Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5–10% of thyroid cancers. Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression-free survival; however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis and new therapeutic approaches for cancer. Unfortunately, only few models are available for medullary thyroid carcinoma. This review provides an overview of the state of the art of animal models in medullary thyroid carcinoma and highlights future developments in this field, with the aim of addressing salient features and clinical relevance.


2017 ◽  
Vol 23 ◽  
pp. 179
Author(s):  
Sandeep Donagaon ◽  
Pramila Kalra ◽  
Anil Kumar ◽  
K. Harish ◽  
Shamim Sheik ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document